Abstracts tagged "immunology"

Abstract Number: 0105 • ACR Convergence 2023
Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis
Yin Long¹, Jiuliang zhao², Mengtao Li² and Xiaofeng Zeng², ¹Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by the presence of pathogenic autoantibodies. The key immune cell subsets change in PAPS patients…
Abstract Number: 0906 • ACR Convergence 2023
Paired Autoantibody Specificities from Serum and Immune Complexes Do Not Fully Explain the Circulating Immune Complex Load in Systemic Lupus Erythematosus: A Study on 530 Patients
Enrico Fuzzi¹, Anna Svanqvist², Christine Westerberg², Agneta Zickert³, Iva Gunnarsson⁴, Johan Rönnelid² and Elisabet Svenungsson⁵, ¹Karolinska University Hospital, Stockholm, Sweden, ²Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden, ³Karolinska University Hospital, Stockholm, Sweden, Stocksund, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypical autoimmune disease where autoantibody production and immune complex (IC) formation play a key role. Which antibodies contribute…
Abstract Number: 1676 • ACR Convergence 2023
Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology
Paula David¹, Thomas Macleod², Yu Shi³, Payal Ganguly¹, Cedric Duval³, Mark Harland¹, Chi Wong¹, Benazir Saleem⁴ and Dennis McGonagle⁵, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, ²University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) patients treated with Janus Kinase inhibitors (JAKi) have reportedly higher venous thromboembolism (VTE) risk and atherosclerotic-related complications including myocardial infarction (1).Although…
Abstract Number: 2242 • ACR Convergence 2023
Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes
M. Elaine Husni¹, Vinod Chandran², Jeffrey Lisse³, Rebecca Bolce³, Carlos Diaz³, Baojin Zhu³, Elaine Lui⁴ and Laura Coates⁵, ¹Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Brightech International, An Everest Clinical Research Company, Somerset, NJ, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a chronic and progressive disease characterized by high rates of early joint erosions, which have been associated with impaired quality…
Abstract Number: 111 • 2023 Pediatric Rheumatology Symposium
Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center
Omar Mostafa, Sharon Bout-Tabaku, Buthaina Al-Adba, Ahmad Kaddourah, Abubakr Imam, Ibrahim Shatat and Mohammed Yousuf Karim, Sidra Medicine, Ar-Rayyan, Qatar
Background/Purpose: Hypogammaglobulinemia is an under-recognized complication of B-cell targeted therapies (BCTT) in both autoimmune diseases (AID) and malignancy. Hypogammaglobulinemia may be transient or persistent, and…
Abstract Number: L03 • ACR Convergence 2022
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
Jay Tuttle¹, Edit Drescher², Jesus Abraham Simón-Campos³, Paul Emery⁴, Maria Greenwald⁵, Alan Kivitz⁶, Hyungmin Rha¹, Pia Yachi¹, Christina Kiley¹ and Ajay Nirula⁷, ¹Eli Lilly and Company, Indianapolis, IN, ²Csolnoky Ferenc Hospital, Veszprém, Hungary, ³Köhler & Milstein Research/Hospital Agustín O'Horán, Merida, Yucatan, Mexico, ⁴University of Leeds, Leeds, United Kingdom, ⁵Desert Medical Advances, Palm Desert, CA, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Eli Lilly, San Diego, CA
Background/Purpose: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). We hypothesized that peresolimab binding to PD-1,…
Abstract Number: L04 • ACR Convergence 2022
Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine², Soumyaroop Bhattacharya³, Jeffrey Fox⁴, Ernest Meyer⁵, Brian Isett⁵, Riyue Bao⁶, Tullia Bruno⁶ and Christopher Ritchlin⁷, ¹University of Rochester, Rochester, NY, ²ORNA Tx, Southborough, MA, ³Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, ⁴CMSR, University of Rochester Medical Center, Rochester, NY, ⁵UPMC Hillman Cancer Center, Pittsburgh, PA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Rochester Medical Center, Rochester, NY
Background/Purpose: A pivotal clinical characteristic of psoriatic arthritis (PsA) is disease manifestations in several domains (skin, entheses, joints, spine) and multiple domain involvement is prevalent,…
Abstract Number: L10 • ACR Convergence 2022
Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)
Sarah Julien¹, Emma Briand¹, Bas van der Woning², Leentje de ceuninck³, Rachid zoubari¹, olivier benveniste⁴, laurent drouot¹ and olivier boyer⁵, ¹INSERM U1234, PAn’THER FOCIS Center of Excellence, Rouen, France, ²argenx, Boston, MA, ³argenx, Ghent, Belgium, ⁴AP-HP, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Paris, France, ⁵INSERM U1234, PAn’THER FOCIS Center of Excellence; Rouen University Hospital, Department of Immunology and Biotherapy, Rouen, France
Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is a severe form of myositis characterized by muscle weakness and elevated creatine kinase levels in serum. The most frequent…
Abstract Number: 0161 • ACR Convergence 2022
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
DeAnna Diaz¹, Thomas Vazquez², Nilesh Kodali³, Madison Grinnell⁴, Emily Keyes⁴, Josh Dan⁴, Grant Sprow⁵, Muhammad Bashir⁶, Meena Sharma⁷ and Victoria Werth⁸, ¹Philadelphia College of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³New Jersey Medical School, Coppell, TX, ⁴Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁸University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. Lenabasum, a non-psychoactive cannabinoid type 2 receptor (CB2R) agonist, is…
Abstract Number: 0630 • ACR Convergence 2022
Ferroptosis of CD163+ Tissue Infiltrating Macrophages in Lupus Nephritis
Qi Cheng, Huaxiang Wu and Yan Du, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China
Background/Purpose: Lupus nephritis (LN) is one of the most common complications of systemic lupus erythematosus (SLE), with high morbidity and mortality. Despite a better understanding…
Abstract Number: 0787 • ACR Convergence 2022
Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
Sara Tedeschi¹, Daniel Solomon¹, Yuezhou Chen², Jack Ellrodt¹, Mary Grace Whelan¹, Jacklyn Stratton¹, Keigo Hayashi³, Noah Whiteman², Lin Chen¹, Ifeoluwakiisi Adejoorin¹, Kathryne Marks¹, Emma Gomez-Rivas¹, Deepak Rao¹, Anna Jonsson¹ and Duane Wesemann², ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: DMARDs that treat RA may reduce immune responses to COVID-19 vaccination. We compared measures of humoral and cell-mediated immunity in RA patients before and…
Abstract Number: 1480 • ACR Convergence 2022
Is Lupus Podocytopathy a New Variant of Lupus Nephritis?
Clarice P. Lin¹ and Richard C. Chou², ¹University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Medicine, Buffalo, NY, ²University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Buffalo, NY
Background/Purpose: Kidney disease is a common manifestation of systemic lupus erythematosus (SLE); when it presents as glomerulonephritis also known as lupus nephritis (LN), it predicts…
Abstract Number: 1732 • ACR Convergence 2022
Novel Human Class II MHC Tetramers Detect Rare, Self-Reactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Shawn Mahmud, Thamotharampillai Dileepan, Bryce Binstadt and Marc Jenkins, University of Minnesota, Minneapolis, MN
Background/Purpose: Nearly all patients with mixed connective tissue disease (MCTD) have IgG autoantibodies (autoAb) specific for U170k, a component of the U1-snNRP spliceosomal complex. A…
Abstract Number: 2184 • ACR Convergence 2022
CaMK4 Controls the Humoral Response via the T Follicular Helper Compartment and Regulates Autoimmunity
Marc Scherlinger¹, Hao Li², Wenliang Pan², Maria Tsokos¹ and George Tsokos², ¹BIDMC Harvard University, Boston, MA, ²Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a dysregulated T cell compartment and production of autoantibodies leading to organ damage. We previously identified that…
Abstract Number: 0218 • ACR Convergence 2022
A Web-based Education Program Improves Health Care Provider Knowledge for the Care of Cancer Patients Receiving Immunotherapy Who Develop Rheumatic Immune-related Complications, and Those with Pre-existing Rheumatic Disease: An Initiative of CanRIO
Janet Roberts¹, Keith Lau², Daniel Ennis³, Marie Hudson⁴, Shahin Jamal³, Steven Katz² and Carrie Ye², ¹Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montréal, QC, Canada
Background/Purpose: Immunotherapy has revolutionized the treatment of many advanced stage malignancies. These agents harness the immune system to fight cancer. However, use of these agents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].